Redefining Radial Closure.
Clinically. Comfortably. Clearly.
Video: Transradial Technologies Inc - The Big Idea CONNECTpreneur Networking and Pitch Extravaganza
SĀPH™ (Suction Activated Patent Hemostasis) is the first and only radial closure device that works with blood flow, not against it.
Leveraging a proprietary suction mechanism, it achieves hemostasis by gently drawing the artery to a soft external seal—without circumferential or downward compression. SĀPH is designed to help minimize the risk of Radial Artery Occlusion (RAO), reduce post-procedure staff burden, and enhance patient comfort.
Developed by a leading interventional cardiologist, SĀPH emphasizes efficiency and simplicity—supporting smoother procedures, preserving future access, and redefining the standard for pain-free closure.
Why SĀPH matters
When was the last time you had a real conversation about improving radial closure–RAO, comfort, staff time?
There are limitations to the conventional radial compression mechanisms of action.
Radial access is now the gold standard.
60% of PCIs in the U.S. use radial (up from 14% in 2011) [4]
Chosen for: Safety, speed, and patient comfort
But closure hasn’t kept up.
No real innovation in closure devices since radial’s rise
Most still rely on circumferential or occlusive compression.
Until now.
SĀPH is designed to streamline radial closure and reduce staff burden.
Precise Alignment
SĀPH features a notch-guided design to support accurate positioning over the access site — helping clinicians align closure with confidence.
Targeted Closure Support
SĀPH is a completely topical system — nothing subdermal. Its integrated keel element supports precise apposition at the arteriotomy site, enabling effortless closure without introducing material beneath the skin.
Predictable Deployment
A simplified design with intuitive visual markers allows consistent setup and reproducibility across a range of experience levels.
Efficient Hemostasis
SĀPH utilizes a proprietary suction-based mechanism to gently approximate the arteriotomy up against the subdermal tissue —promoting effective seal formation without circumferential compression and blocking flow.
Streamlined Workflow
SĀPH reduces complexity at the bedside: no manual pressure, no incremental adjustments, and fewer post-procedure checks. Clinicians know when they’re done — and can move on with confidence.
Evidence at a Glance
“The current hemo static therapies take time and create repetitive tasks from the nursing staff to remove the air. I see that the air removal protocols cannot realistically be followed.
Also, radial artery occlusion is a growing issue. Patients are coming in, sometimes at a young age and your typical CAD patient is going to require multiple caths throughout their lifetime, we hate to lose an access site.”
Bailey Estes
AGNP-C, MSN; Cardiac Cath Lab Scrub Nurse and Researcher; Co-Chair of the ACC Cardiovascular Team Communications Work Group; Cath Lab Digest Editorial Board Greater Abilene Area
About us
Transradial Technologies, Inc. is a medical device company focused on developing a novel, minimally invasive transradial vascular closure device.
Transradial Technologies, Inc. has worldwide and exclusive rights to the technology via an agreement with Transradial Holdings, Inc.
1. PubMed J Invasive Cardiol. 2021 Feb;33(2):E84-E90. Epub 2021 Jan 21. 2. Berger PB. Cath Lab Digest/CIToday. Sept/Oct 2011 3. Avdikos G, et al. Cardiovasc Diagn Ther. 2017;7(3):305-316. doi:10.21037/cdt.2017.03.14 4. Moussa ID et al. J Am Coll Cardiol. 2013;61(8):812–817. doi:10.1016/j.jacc.2012.11.050 5. PubMed Central 2016 Aug 3;3(2):e000397. doi: 10.1136/openhrt-2015-000397